1.80

3.45% 0.06

After Hours: 1.79 -0.01 -0.56%

Gain Therapeutics Inc (GANX)

Overview News Price History Option Chain Financials Why GANX Down? Discussions Forecast

Gain Therapeutics Inc stock is traded at $1.80, with a volume of 149.57K. It is up +3.45% in the last 24 hours and down -25.00% over the past month. Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Previous Close:

$1.74

Open:

$1.75

24h Volume:

149.57K

Relative Volume:

0.64

Market Cap:

$51.96M

Revenue:

$210.70K

Net Income/Loss:

$-21.37M

P/E Ratio:

-1.6364

EPS:

-1.1

Net Cash Flow:

$-21.10M

1W Performance:

+13.92%

1M Performance:

-25.00%

6M Performance:

-35.02%

1Y Performance:

-43.40%

1-Day Range:

$1.70

$1.82

1-Week Range:

$1.54

$1.89

52-Week Range:

$0.89

$3.65

Gain Therapeutics Inc Stock (GANX) Company Profile

Name

Gain Therapeutics Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

(301) 500-1556

Address

4800 HAMPDEN LANE, BETHESDA

Employee

Twitter

Next Earnings Date

2025-03-26

Latest SEC Filings

GANX's Discussions on Twitter

Compare GANX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GANX Gain Therapeutics Inc	1.80	51.96M	210.70K	-21.37M	-21.10M	-1.10
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-06-24	Initiated	ROTH MKM	Buy
Aug-14-24	Resumed	Oppenheimer	Outperform
Apr-12-21	Initiated	BTIG Research	Buy
Apr-12-21	Initiated	Oppenheimer	Outperform

Gain Therapeutics Inc Stock (GANX) Latest News

Apr 16, 2025

CRISPR Therapeutics (NasdaqGM:CRSP) Sees 25% Price Increase Over Last Week - Yahoo Finance

Apr 16, 2025

Viking Therapeutics Stock Pops But Struggles to Hold Gains - TradingView

Apr 16, 2025

Apr 15, 2025

NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback - Yahoo Finance

Apr 15, 2025

Why Viking Therapeutics, Inc. (VKTX) Skyrocketed On Monday? - Yahoo Finance

Apr 15, 2025

Apr 12, 2025

Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns - Yahoo Finance

Apr 12, 2025

Apr 11, 2025

Is Gain Therapeutics (GANX) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Insider Monkey

Apr 11, 2025

Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Yahoo Finance

Apr 11, 2025

Apr 10, 2025

Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn - Insider Monkey

Apr 10, 2025

Gain Therapeutics Unveils New Parkinson’s Treatment Data - TipRanks

Apr 10, 2025

Gain Therapeutics reports progress in Parkinson's disease study - Investing.com

Apr 10, 2025

Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update - The Manila Times

Apr 10, 2025

Apr 08, 2025

Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com

Apr 08, 2025

Apr 04, 2025

Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.20 Average Price Target from Analysts - Defense World

Apr 04, 2025

Apr 03, 2025

Chardan Capital Reiterates “Buy” Rating for Gain Therapeutics (NASDAQ:GANX) - Defense World

Mar 30, 2025

Mar 28, 2025

Optimistic Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Developments and Stable Financial Position - TipRanks

Mar 28, 2025

Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call - The Manila Times

Mar 28, 2025

New Clinical Trial Details: Gain's Innovative Parkinson's Treatment Heads to Major Conference - Stock Titan

Mar 28, 2025

Gain Therapeutics Announces Poster Presentation at AD/PD 2025 - Yahoo Finance

Mar 28, 2025

Gain Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Mar 28, 2025

Mar 27, 2025